Advancements in gene editing technologies such as the CRISPR-Cas system have transformed the therapeutic landscape, opening up new possibilities to treat a variety of diseases, including genetic disorders and malignancies.
It has propelled the nucleic acid therapeutics industry growth by assisting in precise genetic changes and targeted correction of genetic mutations. This has led to investment from both academic and commercial sectors, with gene editing technologies' great precision and efficiency expected to generate breakthrough medications and cures.
Introduction of synthetic oligonucleotides with precise chemical changes have increased their stability and cellular uptake, overcoming disadvantages such as low stability and poor physicochemical qualities.
This has increased the therapeutic efficacy and safety profiles of these medicines, resulting in significant nucleic acid therapeutics market development.
Advances in genetic research and biotechnology are propelling the nucleic acid therapeutics market value. These medicines, which include antisense oligonucleotides (ASOs), RNA interference (RNAi), and RNA aptamers, provide targeted treatments for a range of genetic abnormalities, infectious diseases, and malignancies.
ASOs have the largest market share due to their strong therapeutic properties; they are effective in treating rare genetic disorders such as Duchenne muscular dystrophy and spinal muscular atrophy.
RNAi medicines, with their great specificity in gene silencing, are expected to witness substantial market progress, fueled by successful drugs such as patisiran and givosiran. RNA aptamers, albeit being rare, show great potential because of their unique targeting capabilities.
Hospitals are the principal end-users of these medicines, due to their sophisticated diagnostic and therapeutic infrastructure. Nucleic acid treatments are also in high demand due to their ability to address unmet medical needs, and providing novel therapy choices when established medications fail.
Overall, the nucleic acid therapies market is expected to grow significantly, owing to ongoing innovations, increase in prevalence of genetic abnormalities, and surge in applications in a variety of medical sectors.
| Attribute | Detail |
|---|---|
| Drivers |
|
The creation of synthetic oligonucleotides has resulted in substantial advances in nucleic acid treatments. To improve their medicinal capabilities, synthetic oligonucleotides undergo certain chemical changes. These alterations can take place at three different sites: the nucleobase, the ribofuranose unit, and the phosphate backbone.
Altering the nucleobase and ribose units can shield oligonucleotides against enzymatic damage, thus enhancing their stability within the body, whereas modification of the phosphate backbone can make nucleotide chains less negatively charged, thus promoting their cellular uptake and target localization.
Modifications of chemical structure of genes address the fundamental constraints of native oligonucleotides, which include low stability and poor physicochemical characteristics. As a result, these changes vividly improve the pharmacokinetic characteristics of oligonucleotide-based treatments, making them more promising for clinical usage.
Because of their increased stability and efficiency, nucelic acid based drugs can now be used to treat a wide spectrum of ailments, including genetic abnormalities and malignancies.
As a result, the improved efficacy and safety profiles of the new synthetic oligonucleotides and innovative gene editing technologies are fueling the nucleic acid therapies market size.
The nucleic acid therapeutics market segmentation based on product includes Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi), and RNA Aptamers. Anti-Sense Oligonucleotides (ASOs) have excellent therapeutic qualities because of their capacity to specifically target and modify gene expression.
Antisense Oligonucleotides (ASOs) can bind and cause degeneration to RNA motifs they are complements of and block the RNA from being converted into protein. It is this accuracy in action that allows these molecules to largely silence disease causing genes by targeting only them.
Furthermore, ASOs can be engineered to circumvent the core dogma of molecular biology, providing a therapeutic option for diseases where typical small molecule medicines or biologics are inadequate.
Their applicability covers a wide spectrum of ailments, including genetic abnormalities, malignancies, and viral infections. ASOs' high specificity, better pharmacokinetic characteristics, and broad applicability highlight their huge therapeutic potential, which contributes to their significant nucleic acid therapeutics market share.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
The nucleic acid therapies market analysis shows that North America dominates the landscape. Excellent research and development infrastructure, robust regulatory environment, and high prevalence of genetic abnormalities and diseases treated with these therapies are driving market dynamics in the region.
North America also receives significant financial support from both the public and commercial sectors, such as government initiatives, venture capital investments, and academic-industry alliances.
The United States, in particular, is home to prominent biotechnology and pharmaceutical businesses that invest in cutting-edge technologies such as CRISPR-Cas gene editing and synthetic oligonucleotides.
The region's well-established regulatory system, which includes clear standards from agencies such as the FDA, promotes innovation and supports the timely launch of innovative treatments.
Good legislation and more clinical trials are driving the nucleic acid therapeutics market revenue in Europe. Furthermore, with improved technology and access to better healthcare, Asia Pacific is becoming a lucrative market.
Latin America, the Middle East, and Africa have prospects for expanding their markets due to improved healthcare infrastructure and surge in awareness.
The market is highly competitive and has a strong presence of key players. The nucleic acid therapeutics market report highlights that leading players are adopting strategies such as acquisition and launch of new products.
Alynylam Pharmaceutials, Inc., BioNTech, Ionis Pharmaceuticals, Inc., Moderna, Nippon Shinyaku, Novartis, Pfizer, Sarepta Therapeutics, Biogen Inc., Genzyme Sanofi, and Percheron Therapeutics Ltd. are the prominent nucleic acid therapeutics market manufacturers.
Key players have been profiled in the nucleic acid therapeutics market research report, based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Value in 2023 | US$ 6.0 Bn |
| Forecast (Value) in 2034 | US$ 22.1 Bn |
| Growth Rate (CAGR) | 12.8% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 6.0 Bn in 2023
It is projected to reach more than US$ 22.1 Bn by the end of 2034
The CAGR is anticipated to be 12.8% from 2024 to 2034
Advancements in chemical modification and innovative gene editing technologies
In terms of product, the Anti-Sense Oligonucleotides (ASO) segment accounted for major share in 2023
North America is expected to account for major share during the forecast period
Alynylam Pharmaceutials, Inc., BioNTech, Ionis Pharmaceuticals, Inc., Moderna, Nippon Shinyaku, Novartis, Pfizer, Sarepta Therapeutics, Biogen Inc., Genzyme Sanofi, and Percheron Therapeutics Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nucleic Acid Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario by Countries
5.3. Technological Advancement
5.4. Reimbursement Scenario
5.5. PESTEL Analysis
5.6. Porter’s Five Force Analysis
5.7. Impact Analysis on Market
5.8. Investment Scenario
5.9. Unmet Needs in Current Treatment Landscape
6. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product, 2020-2034
6.3.1. Anti-Sense Oligonucleotides (ASO)
6.3.2. RNA Interference (RNAi)
6.3.3. RNA Aptamers
6.4. Market Attractiveness By Product
7. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2020-2034
7.3.1. Autoimmune Disorders
7.3.2. Infectious Diseases
7.3.3. Genetic Disorders
7.3.4. Cancer
7.3.5. Others
7.4. Market Attractiveness By Indication
8. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2020-2034
8.3.1. Hospitals
8.3.2. Physicians’ Offices
8.3.3. Others
8.4. Market Attractiveness By End-user
9. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Nucleic Acid Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Product, 2020-2034
10.2.1. Anti-Sense Oligonucleotides (ASO)
10.2.2. RNA Interference (RNAi)
10.2.3. RNA Aptamers
10.3. Market Value Forecast By Indication, 2020-2034
10.3.1. Autoimmune Disorders
10.3.2. Infectious Diseases
10.3.3. Genetic Disorders
10.3.4. Cancer
10.3.5. Others
10.4. Market Value Forecast By End-user, 2020-2034
10.4.1. Hospitals
10.4.2. Physicians’ Offices
10.4.3. Others
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Indication
10.6.3. By End-user
10.6.4. By Country
11. Europe Nucleic Acid Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product, 2020-2034
11.2.1. Anti-Sense Oligonucleotides (ASO)
11.2.2. RNA Interference (RNAi)
11.2.3. RNA Aptamers
11.3. Market Value Forecast By Indication, 2020-2034
11.3.1. Autoimmune Disorders
11.3.2. Infectious Diseases
11.3.3. Genetic Disorders
11.3.4. Cancer
11.3.5. Others
11.4. Market Value Forecast By End-user, 2020-2034
11.4.1. Hospitals
11.4.2. Physicians’ Offices
11.4.3. Others
11.5. Market Value Forecast By Country/Sub-region, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Indication
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product, 2020-2034
12.2.1. Anti-Sense Oligonucleotides (ASO)
12.2.2. RNA Interference (RNAi)
12.2.3. RNA Aptamers
12.3. Market Value Forecast By Indication, 2020-2034
12.3.1. Autoimmune Disorders
12.3.2. Infectious Diseases
12.3.3. Genetic Disorders
12.3.4. Cancer
12.3.5. Others
12.4. Market Value Forecast By End-user, 2020-2034
12.4.1. Hospitals
12.4.2. Physicians’ Offices
12.4.3. Others
12.5. Market Value Forecast By Country/Sub-region, 2020-2034
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Indication
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product, 2020-2034
13.2.1. Anti-Sense Oligonucleotides (ASO)
13.2.2. RNA Interference (RNAi)
13.2.3. RNA Aptamers
13.3. Market Value Forecast By Indication, 2020-2034
13.3.1. Autoimmune Disorders
13.3.2. Infectious Diseases
13.3.3. Genetic Disorders
13.3.4. Cancer
13.3.5. Others
13.4. Market Value Forecast By End-user, 2020-2034
13.4.1. Hospitals
13.4.2. Physicians’ Offices
13.4.3. Others
13.5. Market Value Forecast By Country/Sub-region, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Indication
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product, 2020-2034
14.2.1. Anti-Sense Oligonucleotides (ASO)
14.2.2. RNA Interference (RNAi)
14.2.3. RNA Aptamers
14.3. Market Value Forecast By Indication, 2020-2034
14.3.1. Autoimmune Disorders
14.3.2. Infectious Diseases
14.3.3. Genetic Disorders
14.3.4. Cancer
14.3.5. Others
14.4. Market Value Forecast By End-user, 2020-2034
14.4.1. Hospitals
14.4.2. Physicians’ Offices
14.4.3. Others
14.5. Market Value Forecast By Country/Sub-region, 2020-2034
14.5.1. GCC
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Indication
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2023)
15.3. Company Profiles
15.3.1. Alynylam Pharmaceutials, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. BioNTech
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Ionis Pharmaceuticals, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Moderna
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Nippon Shinyaku
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Novartis
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Pfizer
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Sarepta Therapeutics
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Biogen Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Genzyme Sanofi
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Percheron Therapeutics Ltd.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
List of Tables
Table 01: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 02: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
Table 03: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 4: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Region, 2020-2034
Table 5: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 6: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 7: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
Table 8: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 9: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 11: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
Table 12: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 15: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
Table 16: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 17: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 19: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
Table 20: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 23: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
Table 24: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Nucleic Acid Therapeutics Market Size, by Product, 2023
Figure 02: Global Nucleic Acid Therapeutics Market share (%), by Product, 2023
Figure 03: Global Nucleic Acid Therapeutics Market Size, by Indication, 2023
Figure 04: Global Nucleic Acid Therapeutics Market share (%), by Indication, 2023
Figure 05: Global Nucleic Acid Therapeutics Market Size, by End-user, 2023
Figure 06: Global Nucleic Acid Therapeutics Market share (%), by End-user, 2023
Figure 07: Global Nucleic Acid Therapeutics Market, By Region 2023 and 2034
Figure 8: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020-2034
Figure 9: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
Figure 10: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023
Figure 11: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2034
Figure 12: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
Figure 13: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Anti-Sense Oligonucleotides (ASO), 2020-2034
Figure 14: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Anti-Sense Oligonucleotides (ASO), 2023 and 2034
Figure 15: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by RNA Interference (RNAi) , 2020-2034
Figure 16: Global Nucleic Acid Therapeutics Market Value Share Analysis, RNA Interference (RNAi) , 2023 and 2034
Figure 17: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by RNA Aptamers, 2020-2034
Figure 18: Global Nucleic Acid Therapeutics Market Value Share Analysis, by RNA Aptamers, 2023 and 2034
Figure 19: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
Figure 20: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023
Figure 21: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2034
Figure 22: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
Figure 23: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Autoimmune Disorders (ASO), 2020-2034
Figure 24: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Autoimmune Disorders, 2023 and 2034
Figure 25: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Infectious Diseases, 2020-2034
Figure 26: Global Nucleic Acid Therapeutics Market Value Share Analysis, Infectious Diseases, 2023 and 2034
Figure 27: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Genetic Disorders, 2020-2034
Figure 28: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Genetic Disorders, 2023 and 2034
Figure 29: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Cancer , 2020-2034
Figure 30: Global Nucleic Acid Therapeutics Market Value Share Analysis, Cancer , 2023 and 2034
Figure 31: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Others, 2020-2034
Figure 32: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Others, 2023 and 2034
Figure 33: Global Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 34: Global Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023
Figure 35: Global Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2034
Figure 36: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 37: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Hospitals, 2020-2034
Figure 38: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Hospitals, 2023 and 2034
Figure 39: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Physicians’ Offices , 2020-2034
Figure 40: Global Nucleic Acid Therapeutics Market Value Share Analysis, Physicians’ Offices , 2023 and 2034
Figure 41: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Others , 2020-2034
Figure 42: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Others , 2023 and 2034
Figure 43: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
Figure 44: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, by Region, 2023-2034
Figure 45: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 46: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
Figure 47: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country, 2023-2034
Figure 48: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
Figure 49: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
Figure 50: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
Figure 51: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
Figure 52: North America Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 53: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 54: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 55: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 56: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
Figure 57: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
Figure 58: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
Figure 59: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
Figure 60: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
Figure 61: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 62: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 63: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 64: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 65: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
Figure 66: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
Figure 67: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
Figure 68: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
Figure 69: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
Figure 70: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 71: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 72: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 73: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 74: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
Figure 75: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
Figure 76: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
Figure 77: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
Figure 78: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
Figure 79: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 80: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 81: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 82: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 83: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
Figure 84: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
Figure 85: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
Figure 86: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
Figure 87: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
Figure 88: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 89: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Nucleic Acid Therapeutics Market
